Citations

Clear

2429 citation(s) found for "Shah, SS".

Implementation of Shared Decision Making in Cardiovascular Care
Coylewright, Megan , Frosch, Dominick L. , Shah, Nilay D. , Hess, Erik P.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 23, 2014 | Volume: 7 | Issue: 5 | Pages: 797-803

10.1161/circoutcomes.113.000351 | PMID 25052074 Get It

Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality
Xu, Hua , Aldrich, Melinda C. , Peterson, Neeraja B. , Levy, Mia , Shah, Anushi, Han, Xue, Ruan, Xiaoyang , Jiang, Min , Li, Ying , Julien, Jamii St., Friedman, Carol, Roden, Dan M. , Denny, Joshua C. , Chen, Qingxia , Liu, Hongfang , Dai, Qi , Han, Xue, Warner, Jeremy L. , Roden, Dan M. , Denny, Joshua C

Mayo Clinic

Journal of the American Medical Informatics Association | July 23, 2014 | Volume: 22 | Issue: 1 | Pages: 179-191

10.1136/amiajnl-2014-002649 | PMID 25053577 Get It

Abstract Objectives Drug repurposing, which finds new indications for existing drugs, has received great attention recently. The goal of our work is to assess the feasibility of using electronic health records (EHRs) and automated informatics methods to efficiently validate a recent drug repurposing association of metformin with reduced cancer mortality. Methods By linking two large EHRs from Vanderbilt University Medical Center and Mayo Clinic to their tumor registries, we constructed a cohort including 32 415 adults with a cancer diagnosis at Vanderbilt and 79 258 cancer patients at Mayo from 1995 to 2010. Using automated informatics methods, we further identified type 2 diabetes patients within the cancer cohort and determined their drug exposure information, as well as other covariates such as smoking status. We then estimated HRs for all-cause mortality and their associated 95% CIs using stratified Cox proportional hazard models. HRs were estimated according to metformin exposure, adjusted for age at diagnosis, sex, race, body mass index, tobacco use, insulin use, cancer type, and non-cancer Charlson comorbidity index. Results Among all Vanderbilt cancer patients, metformin was associated with a 22% decrease in overall mortality compared to other oral hypoglycemic medications (HR 0.78; 95% CI 0.69 to 0.88) and with a 39% decrease compared to type 2 diabetes patients on insulin only (HR 0.61; 95% CI 0.50 to 0.73). Diabetic patients on metformin also had a 23% improved survival compared with non-diabetic patients (HR 0.77; 95% CI 0.71 to 0.85). These associations were replicated using the Mayo Clinic EHR data. Many site-specific cancers including breast, colorectal, lung, and prostate demonstrated reduced mortality with metformin use in at least one EHR. Conclusions EHR data suggested that the use of metformin was associated with decreased mortality after a cancer diagnosis compared with diabetic and non-diabetic cancer patients not on metformin, indicating its potential as a chemotherapeutic regimen. This study serves as a model for robust and inexpensive validation studies for drug repurposing signals using EHR data.
Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high‐risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin‐amphotericin co
Abidi, Maheen Z. , Sohail, M. Rizwan , Wilhelm, Mark , Wengenack, Nancy L. , Brumble, Lisa , Shah, Harshal , Hata, D. Jane , McCullough, Ann E. , Wendel, Amy J., Vikram, Holenarasipur R. , Kusne, Shimon , Litzow, Mark R. , Letendre, Louis, Lahr, Brian D. , Poeschla, Eric M. , Walker, Randall C., Cummins, Nathan W. , Vikram, Holenarasipur R. , Sohail, M Rizwan , Abidi, Maheen Z , Abidi, Maheen Z

Mayo Clinic

Mycoses | July 18, 2014 | Volume: 57 | Issue: 11 | Pages: 687-698

10.1111/myc.12222 | PMID 25040241 Get It

SummaryAs invasive mucormycosis (IM) numbers rise, clinicians suspect prior voriconazole worsens IM incidence and severity, and believe combination anti‐fungal therapy improves IM survival. To compare the cumulative incidence (CI), severity and mortality of IM in eras immediately before and after the commercial availability of voriconazole all IM cases from 1995 to 2011 were analysed across four risk‐groups (hematologic/oncologic malignancy (H/O), stem cell transplantation (SCT), solid organ transplantation (SOT) and other), and two eras, E1 (1995–2003) and E2, (2004–2011). Of 101 IM cases, (79 proven, 22 probable): 30 were in E1 (3.3/year) and 71 in E2 (8.9/year). Between eras, the proportion with H/O or SCT rose from 47% to 73%, while ‘other’ dropped from 33% to 11% (P = 0.036). Between eras, the CI of IM did not significantly increase in SCT (P = 0.27) or SOT (P = 0.30), and patterns of anatomic location (P = 0.122) and surgical debridement (P = 0.200) were similar. Significantly more patients received amphotericin‐echinocandin combination therapy in E2 (31% vs. 5%, P = 0.01); however, 90‐day survival did not improve (54% vs. 59%, P = 0.67). Since 2003, the rise of IM reflects increasing numbers at risk, not prior use of voriconazole. Frequent combination of anti‐fungal therapy has not improved survival.
GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction
Anstrom, Kevin J. , Hernandez, Adrian F. , Redfield, Margaret M. , Cappola, Thomas P. , Margulies, Kenneth B. , Shah, Monica R, Shah, Monica , Braunwald, Eugene , Hernandez, Adrian

Mayo Clinic

Circulation: Heart Failure | July 15, 2014 | Volume: 7 | Issue: 4 | Pages: 673-679

10.1161/circheartfailure.114.000346 | PMID 25028349 Get It

Optum Labs: Building A Novel Node In The Learning Health Care System
Wallace, Paul , Shah, Nilay D. , Dennen, Taylor, Bleicher, Paul A. , Crown, William H.

Mayo Clinic

Health Affairs | July 8, 2014 | Volume: 33 | Issue: 7 | Pages: 1187-1194

10.1377/hlthaff.2014.0038 | PMID 25006145 Get It

Effect of Multiple Chronic Diseases on Health Care Expenditures in Childhood
Zhong, Wenjun , Finnie, Dawn M., Shah, Nilay D. , Wagie, Amy E., Sauver, Jennifer L. St. , Jacobson, Debra J., Naessens, James M. , St Sauver, Jennifer L, St Sauver, Jennifer L

Mayo Clinic

Journal of Primary Care & Community Health | July 8, 2014 | Volume: 6 | Issue: 1 | Pages: 2-9

10.1177/2150131914540916 | PMID 25001922 Get It

Objectives: To examine multiple chronic conditions and related health care expenditures in children. Methods: Retrospective cohort study of all dependents of Mayo Clinic employees aged 0-17 on Jan 1, 2004 with continuous health benefits coverage for 4 years (N=14,727). Chronic conditions, health care utilization, and associated expenditures were obtained from medical and pharmacy claims. Results: The most prevalent chronic conditions were asthma/chronic obstructive pulmonary disease (12%), allergic rhinitis (11%), and behavior problems (9%). The most costly conditions were congenital anomalies, asthma/chronic obstructive pulmonary disease, and behavior problems ($9602, $4335, and $5378 annual cost per child, respectively). Annual health care expenditures increased substantially with the number of chronic conditions, and a small proportion of children with multiple chronic conditions accounted for a large proportion of health care costs. In addition, those with multiple chronic conditions were more likely to persist in the top 10th percentile spender group in year-to-year spending. Conclusion: Children with multiple chronic conditions accounted for a large proportion of health care expenditures. These children were also likely to persist as high spenders in the 4-year time frame. Further research into effective ways to manage the health care delivery for children with multiple chronic conditions is needed.
Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010
Ross, Joseph S. , Houten, Holly K. Van , Beran, David , Yudkin, John , Shah, Nilay D. , Van Houten, Holly K, Lipska, Kasia J. , Ross, Joseph S

Mayo Clinic

JAMA | June 10, 2014 | Volume: 311 | Issue: 22 | Pages: 2331

10.1001/jama.2014.6316 | PMID 24915266 Get It

Vasodilator‐stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11‐dependent plasma membrane targeting of transforming growth factor beta receptors
Tu, Kangsheng , Li, Jiachu, Verma, Vikas , Liu, Chunsheng , Billadeau, Daniel D. , Lamprecht, Georg , Xiang, Xiaoyu, Dhanasekaran, Renumathy , Roberts, Lewis R. , Shah, Vijay H. , Kang, Ningling , Guo, Luyang , Roberts, Lewis R , Dhanasekaran, Renumathy

Mayo Clinic

Hepatology | June 10, 2014 | Volume: 61 | Issue: 1 | Pages: 361-374

10.1002/hep.27251 | PMID 24917558 Get It

Liver microenvironment is a critical determinant for development and progression of liver metastasis. Under transforming growth factor beta (TGF‐β) stimulation, hepatic stellate cells (HSCs), which are liver‐specific pericytes, transdifferentiate into tumor‐associated myofibroblasts that promote tumor implantation (TI) and growth in the liver. However, the regulation of this HSC activation process remains poorly understood. In this study, we tested whether vasodilator‐stimulated phosphoprotein (VASP) of HSCs regulated the TGF‐β‐mediated HSC activation process and tumor growth. In both an experimental liver metastasis mouse model and cancer patients, colorectal cancer cells reaching liver sinusoids induced up‐regulation of VASP and alpha‐smooth muscle actin (α‐SMA) in adjacent HSCs. VASP knockdown in HSCs inhibited TGF‐β‐mediated myofibroblastic activation of HSCs, TI, and growth in mice. Mechanistically, VASP formed protein complexes with TGF‐β receptor II (TβRII) and Rab11, a Ras‐like small GTPase and key regulator of recycling endosomes. VASP knockdown impaired Rab11 activity and Rab11‐dependent targeting of TβRII to the plasma membrane, thereby desensitizing HSCs to TGF‐β1 stimulation. Conclusions: Our study demonstrates a requirement of VASP for TGF‐β‐mediated HSC activation in the tumor microenvironment by regulating Rab11‐dependent recycling of TβRII to the plasma membrane. VASP and its effector, Rab11, in the tumor microenvironment thus present therapeutic targets for reducing TI and metastatic growth in the liver. (Hepatology 2015;61:361–374)
Thyroid fine‐needle aspiration cytology: Performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non‐GYN Assessment program thyroid fine‐needle performance data
Eilers, Stan G., LaPolice, Paula, Mukunyadzi, Perkins , Kapur, Umesh, Spiczka, Amy Wendel, Saleh, Husain A., Nunez, Amberly L., Balachandran, Indra, Clark, Jennifer , Lemon, Larry, Eilers, Stanley G., Shah, Ajay M. , Adeniran, Adebowale

Mayo Clinic

Cancer Cytopathology | June 9, 2014 | Volume: 122 | Issue: 10 | Pages: 745-750

10.1002/cncy.21440 | PMID 24913410 Get It

BACKGROUNDFine‐needle aspiration of the thyroid is a common procedure, with an established role in reducing unnecessary thyroid surgery and identifying neoplasms and malignancies.METHODSThe study evaluated 1558 responses in the American Society for Clinical Pathology (ASCP) Non‐GYN Assessment program of aspirates of thyroid neoplasms and malignancies and placed them into the following groups: group A (target or correct interpretation), group B (incorrect interpretation as a benign thyroid nodule), group C (incorrect interpretation malignant aspirate as thyroid neoplasm), and group D (malignant diagnosis with incorrect interpretation). In clinical practice, responses in groups A, C, and D would lead to surgical excision, whereas responses in group B would not.RESULTSOf a total of 1558 responses, 78.5% of the responses were in group A, 8.5% in group B, 3.75% in group C, and 9.25% in group D. By individual diagnosis, the group rates were 86.5%, 0%, 11%, and 2.5% for anaplastic thyroid carcinoma; 83%, 5.5%, 4.25%, and 7.25% for papillary thyroid carcinoma; 79%, 7%, 6%, and 8% for medullary thyroid carcinoma; 83.5% 6.75%, 0%, and 9.75% for Hürthle cell neoplasm; and 61%, 22%, 0%, and 17% for follicular neoplasm in groups A, B, C, and D respectively.CONCLUSIONSFine‐needle aspiration was effective in diagnosing thyroid neoplasms and malignancies and in separating thyroid nodules into surgical and nonsurgical categories. Data from a large group of cytology professionals showed good performance; however, there is room for improvement, especially in making specific diagnoses. In particular, follicular neoplasm and follicular variant of papillary thyroid carcinoma were challenging diagnoses for participants. Cancer (Cancer Cytopathol) 2014;122:745–750. © 2014 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Impact of Sociodemographic Patient Characteristics on the Efficacy of Decision Aids
Coylewright, Megan , Inselman, Jonathan , Shah, Nilay D. , Montori, Víctor M. , Ting, Henry H. , Branda, Megan, Inselman, Jonathan W, Shah, Nilay , Hess, Erik, LeBlanc, Annie , Branda, Megan E. , Hess, Erik P. , Montori, Victor M

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 14, 2014 | Volume: 7 | Issue: 3 | Pages: 360-367

10.1161/hcq.0000000000000006 | PMID 24823953 Get It

Background— Decision aids (DAs) increase patient knowledge, reduce decisional conflict, and promote shared decision making (SDM). The extent to which they do so across diverse sociodemographic patient groups is unknown. Methods and Results— We conducted a patient-level meta-analysis of 7 randomized trials of DA versus usual care comprising 771 encounters between patients and clinicians discussing treatment options for chest pain, myocardial infarction, diabetes mellitus, and osteoporosis. Using a random effects model, we examined the impact of sociodemographic patient characteristics (age, sex, education, income, and insurance status) on the outcomes of knowledge transfer, decisional conflict, and patient involvement in SDM. Because of small numbers of people of color in the study population, we were not powered to investigate the role of race. Most patients were aged ≥65 years (61%), white (94%), and women (59%); two thirds had greater than a high school education. Compared with usual care, DA patients gained knowledge, were more likely to know their risk, and had less decisional conflict along with greater involvement in SDM. These gains were largely consistent across sociodemographic patient groups, with DAs demonstrating similar efficacy when used with vulnerable patients such as the elderly and those with less income and less formal education. Differences in efficacy were found only in knowledge of risk in 1 subgroup, with greater efficacy among those with higher education (35% versus 18%; P =0.02). Conclusions— In this patient-level meta-analysis of 7 randomized trials, DAs were efficacious across diverse sociodemographic groups as measured by knowledge transfer, decisional conflict, and patient involvement in SDM. To the extent that DAs increase patient knowledge and participation in SDM, they have potential to impact health disparities related to these factors.